DB:IMU

Stock Analysis Report

Executive Summary

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer.


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has ImmunoGen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMU's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.9%

IMU

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

3.0%

IMU

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: IMU underperformed the German Biotechs industry which returned 10% over the past year.

Return vs Market: IMU underperformed the German Market which returned 12.8% over the past year.


Shareholder returns

IMUIndustryMarket
7 Day-12.9%0.4%-0.9%
30 Day11.2%-3.2%-0.4%
90 Day67.0%4.6%2.3%
1 Year3.0%3.0%10.3%10.0%16.3%12.8%
3 Year106.1%106.1%49.4%47.8%15.8%5.7%
5 Year-28.8%-28.8%13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is ImmunoGen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ImmunoGen undervalued compared to its fair value and its price relative to the market?

41.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IMU (€4.98) is trading below our estimate of fair value (€8.54)

Significantly Below Fair Value: IMU is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IMU is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IMU is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMU has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.


Next Steps

Future Growth

How is ImmunoGen forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

22.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMU's revenue (25.5% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: IMU's revenue (25.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMU's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ImmunoGen performed over the past 5 years?

-12.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMU is currently unprofitable.

Growing Profit Margin: IMU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMU is unprofitable, and losses have increased over the past 5 years at a rate of -12.2% per year.

Accelerating Growth: Unable to compare IMU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: IMU's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is ImmunoGen's financial position?


Financial Position Analysis

Short Term Liabilities: IMU has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: IMU has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: IMU is debt free.

Reducing Debt: IMU's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: IMU has a low level of unsold assets or inventory.

Debt Coverage by Assets: IMU has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMU has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMU has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -9.3% each year.


Next Steps

Dividend

What is ImmunoGen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate IMU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IMU's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMU's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Mark Enyedy (55yo)

3.8yrs

Tenure

US$8,823,242

Compensation

Mr. Mark J. Enyedy has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and has been its interim principal financial officer since November 26, 2018. Mr. Enyedy has over ...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD8.82M) is above average for companies of similar size in the German market ($USD1.20M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Mark Enyedy
President3.8yrsUS$8.82m0.28% $2.4m
Craig Barrows
Executive VP12.3yrsUS$2.12m0.093% $805.6k
Courtney O'Konek
Senior Director of Corporate Communications & Investor Relations0yrsno datano data
Audrey Bergan
VP & Chief Human Resources Officer1.6yrsno datano data
Theresa Wingrove
Senior Vice President of Regulatory Affairs & Quality0yrsno data0.050% $431.5k
Anna Berkenblit
Senior VP & Chief Medical Officer4.8yrsUS$998.87k0.071% $617.0k

4.3yrs

Average Tenure

58yo

Average Age

Experienced Management: IMU's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Enyedy
President3.8yrsUS$8.82m0.28% $2.4m
Stephen McCluski
Independent Chairman10.3yrsUS$266.62kno data
Dean Mitchell
Independent Director8.1yrsUS$230.62k0.0057% $49.8k
Kristine Peterson
Independent Director8.1yrsUS$237.32kno data
Richard Wallace
Independent Director12.3yrsUS$233.62kno data
Stuart Arbuckle
Independent Director2.1yrsUS$428.38kno data
Mark Goldberg
Independent Director8.3yrsUS$226.89k0.031% $267.9k

8.1yrs

Average Tenure

63yo

Average Age

Experienced Board: IMU's board of directors are considered experienced (8.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.


Top Shareholders

Company Information

ImmunoGen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ImmunoGen, Inc.
  • Ticker: IMU
  • Exchange: DB
  • Founded: 1980
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$942.525m
  • Listing Market Cap: US$867.689m
  • Shares outstanding: 174.22m
  • Website: https://www.immunogen.com

Number of Employees


Location

  • ImmunoGen, Inc.
  • 830 Winter Street
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1989
IMUDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1989
IMUXTRA (XETRA Trading Platform)YesCommon StockDEEURNov 1989
IMGN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 1989

Biography

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 21:06
End of Day Share Price2020/02/21 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.